Stock JAZZ JAZZ PHARMACEUTICALS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
106.3 USD -0.24% Intraday chart for Jazz Pharmaceuticals plc +0.82% -13.56%
Jun. 06 Transcript : Jazz Pharmaceuticals plc Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 02:00 PM
Jun. 01 Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 8,445 9,196 7,831 10,031 7,744 6,702 - -
Enterprise Value (EV) 1 9,415 10,233 13,290 14,874 11,830 10,238 8,910 7,715
P/E ratio 16.4 x 39.1 x -23.1 x -44.5 x 20.2 x 18.1 x 12.4 x 12.3 x
Yield - - - - - - - -
Capitalization / Revenue 3.91 x 3.89 x 2.53 x 2.74 x 2.02 x 1.65 x 1.53 x 1.46 x
EV / Revenue 4.36 x 4.33 x 4.29 x 4.06 x 3.09 x 2.53 x 2.04 x 1.68 x
EV / EBITDA 8.43 x 11.1 x 6.72 x 11.1 x 7.04 x 5.87 x 4.48 x 3.5 x
EV / FCF 12.8 x 11.6 x 17.7 x 12 x 11.1 x 8.54 x 6.51 x 4.82 x
FCF Yield 7.82% 8.65% 5.65% 8.36% 9.03% 11.7% 15.4% 20.7%
Price to Book 2.69 x 2.53 x 1.98 x 3.26 x 2.05 x 1.55 x 1.3 x 1.09 x
Nbr of stocks (in thousands) 56,573 55,714 61,470 62,966 62,957 63,040 - -
Reference price 2 149.3 165.0 127.4 159.3 123.0 106.3 106.3 106.3
Announcement Date 2/25/20 2/23/21 3/1/22 3/1/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,162 2,364 3,094 3,659 3,834 4,053 4,368 4,598
EBITDA 1 1,117 917.9 1,978 1,338 1,681 1,745 1,989 2,203
EBIT 1 1,102 899.3 1,425 1,307 1,650 1,712 1,901 2,002
Operating Margin 50.98% 38.05% 46.07% 35.73% 43.04% 42.24% 43.52% 43.54%
Earnings before Tax (EBT) 1 454.3 275.1 -112.8 -372.8 297.9 412.5 638.3 826.2
Net income 1 523.4 238.6 -329.7 -224.1 414.8 432.3 597.7 652.6
Net margin 24.21% 10.1% -10.65% -6.12% 10.82% 10.67% 13.68% 14.19%
EPS 2 9.090 4.220 -5.520 -3.580 6.100 5.887 8.554 8.629
Free Cash Flow 1 736.3 884.6 750.9 1,243 1,068 1,199 1,368 1,600
FCF margin 34.06% 37.43% 24.27% 33.97% 27.86% 29.57% 31.31% 34.79%
FCF Conversion (EBITDA) 65.89% 96.37% 37.96% 92.91% 63.54% 68.7% 68.77% 72.62%
FCF Conversion (Net income) 140.68% 370.74% - - 257.46% 277.27% 228.84% 245.12%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/25/20 2/23/21 3/1/22 3/1/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 896.7 813.7 932.9 940.7 972.1 892.8 957.3 972.1 1,012 902 1,005 1,044 1,095 997 1,047
EBITDA 1 561.1 410.1 418.6 509.9 31.21 405 435.4 421.9 428.7 345.2 430.7 465.9 520.8 - -
EBIT 1 396.5 402.5 410.8 502.3 23.87 397.4 427.9 414.2 421.1 317.2 431.2 466.2 499.6 411.5 467
Operating Margin 44.21% 49.47% 44.04% 53.4% 2.46% 44.51% 44.69% 42.61% 41.61% 35.16% 42.89% 44.66% 45.64% 41.27% 44.61%
Earnings before Tax (EBT) 1 -44.83 6.325 21.01 -60.13 -340 55.1 81.78 99.52 61.53 -1.602 99.07 134.3 180.8 115.8 141.5
Net income 1 -35.35 1.647 34.66 -19.65 -240.7 69.42 104.4 146.8 94.15 -14.62 108.1 154.1 149.8 118.1 143.5
Net margin -3.94% 0.2% 3.72% -2.09% -24.76% 7.78% 10.91% 15.1% 9.3% -1.62% 10.76% 14.76% 13.68% 11.85% 13.7%
EPS 2 -0.5700 0.0300 0.5500 -0.3100 -3.820 1.040 1.520 2.140 1.420 -0.2300 1.447 2.115 2.092 1.670 2.030
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 3/1/22 5/4/22 8/3/22 11/9/22 3/1/23 5/10/23 8/9/23 11/8/23 2/28/24 5/1/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 970 1,037 5,458 4,843 4,087 3,535 2,208 1,013
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.868 x 1.13 x 2.76 x 3.62 x 2.431 x 2.026 x 1.11 x 0.4598 x
Free Cash Flow 1 736 885 751 1,243 1,068 1,199 1,368 1,600
ROE (net income / shareholders' equity) 31.8% 20.8% 26% 26.5% 38% 29.5% 29.8% 26.4%
ROA (Net income/ Total Assets) 9.74% 11.7% 10.5% 8.07% 3.73% 7.58% 7.23% 6.45%
Assets 1 5,371 2,046 -3,127 -2,776 11,114 5,703 8,270 10,122
Book Value Per Share 2 55.40 65.20 64.30 48.80 60.00 68.60 82.10 97.50
Cash Flow per Share 2 13.50 15.90 13.00 20.30 15.20 20.00 19.70 19.50
Capex 1 40.1 15 27.6 29 24 31.7 31.9 34.1
Capex / Sales 1.86% 0.63% 0.89% 0.79% 0.62% 0.78% 0.73% 0.74%
Announcement Date 2/25/20 2/23/21 3/1/22 3/1/23 2/28/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Jazz Pharmaceuticals plc

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
106.3 USD
Average target price
180.3 USD
Spread / Average Target
+69.55%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
JAZZ PHARMACEUTICALS PLC Stock Jazz Pharmaceuticals plc
-13.56% 6.7B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+43.64% 754B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.52% 630B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.58% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.72% 331B
ABBVIE INC. Stock AbbVie Inc.
+8.78% 298B
NOVARTIS AG Stock Novartis AG
+11.70% 217B
ROCHE HOLDING AG Stock Roche Holding AG
-1.76% 216B
PFIZER, INC. Stock Pfizer, Inc.
+0.03% 163B
AMGEN INC. Stock Amgen Inc.
+6.13% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. JAZZ Stock
  4. Financials Jazz Pharmaceuticals plc